CXCL1 Promotes Cell Migration in Hepatocellular Carcinoma by Regulating the MiR-30b-5p/ICAM-1 Axis

Overview

Journal J Cancer

Specialty Oncology

Date 2024 Aug 12

PMID 39132161

Authors

Yi-Hsin Chen

Chih-Chun Chu

Augusta I-Chin Wei

Ju-Fang Liu

Hong-Shiee Lai

Affiliations

Soon will be listed here.

Abstract

Hepatocellular carcinoma (HCC) is a highly lethal cancer with a growing global incidence and is often associated with poor prognosis due to its tendency to metastasize. Intercellular adhesion molecule (ICAM) 1 is a transmembrane protein found in various cancer cells and is associated with the spread of cancer and poor prognosis. Chemokine (C-X-C motif) ligand 1 (CXCL1) is a chemokine that significantly affects the cell motility of various cancers. However, the role of CXCL1 in ICAM-1 expression and in metastasis of hepatocellular carcinoma remains unclear. We determined that CXCL1 expression is positively and significantly associated with advanced-stage tumors in the HCC tissue array. Kaplan-Meier analysis revealed worse overall survival rates in the high CXCL1 expression group, suggesting its potential as a biomarker for cancer progression and stimulating hepatocellular carcinoma cells with CXCL1 enhanced migration abilities by upregulating ICAM-1 expression. CXCL1 was shown to enhance ICAM-1-dependent cell motility by inhibiting miR-30b-5p. This study provides novel evidence that CXCL1 could serve as a therapeutic target for metastasis in hepatocellular carcinoma.

References

Spaks A, Jaunalksne I, Spaka I, Chudasama D, Pirtnieks A, Krievins D . Diagnostic Value of Circulating CXC Chemokines in Non-small Cell Lung Cancer. Anticancer Res. 2015; 35(12):6979-83. View

Motyka J, Gacuta E, Kicman A, Kulesza M, Lawicki P, Lawicki S . Plasma Levels of CXC Motif Chemokine 1 (CXCL1) and Chemokine 8 (CXCL8) as Diagnostic Biomarkers in Luminal A and B Breast Cancer. J Clin Med. 2022; 11(22). PMC: 9693547. DOI: 10.3390/jcm11226694. View

Luo X, Zhang X, Peng J, Chen Y, Zhao W, Jiang X . miR-371b-5p promotes cell proliferation, migration and invasion in non-small cell lung cancer via SCAI. Biosci Rep. 2020; 40(11). PMC: 7672804. DOI: 10.1042/BSR20200163. View

Yuan M, Zhu H, Xu J, Zheng Y, Cao X, Liu Q . Tumor-Derived CXCL1 Promotes Lung Cancer Growth via Recruitment of Tumor-Associated Neutrophils. J Immunol Res. 2016; 2016:6530410. PMC: 4942661. DOI: 10.1155/2016/6530410. View

Witkowska A, Borawska M . Soluble intercellular adhesion molecule-1 (sICAM-1): an overview. Eur Cytokine Netw. 2004; 15(2):91-8. View

Salminen A, Allahyari Z, Gholizadeh S, McCloskey M, Ajalik R, Cottle R . Studies of Transendothelial Migration for Biological and Drug Discovery. Front Med Technol. 2022; 2:600616. PMC: 8757899. DOI: 10.3389/fmedt.2020.600616. View

Benedicto A, Romayor I, Arteta B . Role of liver ICAM-1 in metastasis. Oncol Lett. 2017; 14(4):3883-3892. PMC: 5604125. DOI: 10.3892/ol.2017.6700. View

Zhang X, Li J, Shen F, Lau W . Significance of presence of microvascular invasion in specimens obtained after surgical treatment of hepatocellular carcinoma. J Gastroenterol Hepatol. 2017; 33(2):347-354. DOI: 10.1111/jgh.13843. View

Issekutz T . Lymphocyte homing to sites of inflammation. Curr Opin Immunol. 1992; 4(3):287-93. DOI: 10.1016/0952-7915(92)90078-s. View

10.

Guo X, Xu Y, Wang X, Lin F, Wu H, Duan J . Advanced Hepatocellular Carcinoma with Bone Metastases: Prevalence, Associated Factors, and Survival Estimation. Med Sci Monit. 2019; 25:1105-1112. PMC: 6378855. DOI: 10.12659/MSM.913470. View

11.

Wege H, Li J, Ittrich H . Treatment Lines in Hepatocellular Carcinoma. Visc Med. 2019; 35(4):266-272. PMC: 6738173. DOI: 10.1159/000501749. View

12.

Oudar O, Moreau A, Feldmann G, Scoazec J . Expression and regulation of intercellular adhesion molecule-1 (ICAM-1) in organotypic cultures of rat liver tissue. J Hepatol. 1999; 29(6):901-9. DOI: 10.1016/s0168-8278(98)80117-7. View

13.

Lo H, Shieh J, Chen C, Tsou C, Wu W . Vascular endothelial growth factor induces CXCL1 chemokine release via JNK and PI-3K-dependent pathways in human lung carcinoma epithelial cells. Int J Mol Sci. 2013; 14(5):10090-106. PMC: 3676830. DOI: 10.3390/ijms140510090. View

14.

Sagnelli E, Macera M, Russo A, Coppola N, Sagnelli C . Epidemiological and etiological variations in hepatocellular carcinoma. Infection. 2019; 48(1):7-17. DOI: 10.1007/s15010-019-01345-y. View

15.

Benelli R, Stigliani S, Minghelli S, Carlone S, Ferrari N . Impact of CXCL1 overexpression on growth and invasion of prostate cancer cell. Prostate. 2013; 73(9):941-51. DOI: 10.1002/pros.22640. View

16.

Miyake M, Furuya H, Onishi S, Hokutan K, Anai S, Chan O . Monoclonal Antibody against CXCL1 (HL2401) as a Novel Agent in Suppressing IL6 Expression and Tumoral Growth. Theranostics. 2019; 9(3):853-867. PMC: 6376461. DOI: 10.7150/thno.29553. View

17.

Liu J, Fong Y, Chang K, Kuo S, Chang C, Tang C . FPTB, a novel CA-4 derivative, induces cell apoptosis of human chondrosarcoma cells through mitochondrial dysfunction and endoplasmic reticulum stress pathways. J Cell Biochem. 2011; 112(2):453-62. DOI: 10.1002/jcb.22927. View

18.

Kinzler M, Bankov K, Bein J, Doring C, Schulze F, Reis H . CXCL1 and CXCL6 Are Potential Predictors for HCC Response to TACE. Curr Oncol. 2023; 30(3):3516-3528. PMC: 10046993. DOI: 10.3390/curroncol30030267. View

19.

Wu M, Tong X, Wang D, Wang L, Fan H . Soluble intercellular cell adhesion molecule-1 in lung cancer: A meta-analysis. Pathol Res Pract. 2020; 216(10):153029. DOI: 10.1016/j.prp.2020.153029. View

20.

Wang H, Babic A, Mitchell H, Liu K, Wagner D . Elevated soluble ICAM-1 levels induce immune deficiency and increase adiposity in mice. FASEB J. 2005; 19(8):1018-20. DOI: 10.1096/fj.04-3094fje. View